Last $3.14 USD
Change Today -0.11 / -3.38%
Volume 2.7M
SQNM On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 09/19/14 All times are local (Market data is delayed by at least 15 minutes).

sequenom inc (SQNM) Snapshot

Open
$3.25
Previous Close
$3.25
Day High
$3.30
Day Low
$3.08
52 Week High
07/3/14 - $4.17
52 Week Low
11/6/13 - $1.65
Market Cap
366.3M
Average Volume 10 Days
2.5M
EPS TTM
$-0.57
Shares Outstanding
116.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for SEQUENOM INC (SQNM)

sequenom inc (SQNM) Related Businessweek News

View More BusinessWeek News

sequenom inc (SQNM) Details

Sequenom, Inc., a life sciences company, provides genomic and genetic analysis solutions for the molecular diagnostic and clinical research markets in the United States and internationally. It operates through two segments, Sequenom Center for Molecular Medicine and Sequenom Bioscience. The Sequenom Center for Molecular Medicine segment provides molecular based, laboratory developed tests (LDTs) with a focus principally on prenatal diseases and conditions, and ophthalmological diseases and conditions. Its LDTs include MaterniT21 PLUS LDT, a noninvasive prenatal test (NIPT) to detect fetal chromosomal abnormalities; HerediT CF LDT, a carrier screen test to identify individuals with cystic fibrosis or genetic mutations; SensiGene RHD LDT, a NIPT to determine the presence or absence of fetal Rhesus D factor; and RetnaGene AMD LDT, a genetic test to predict the risk of a patient with dry or early stage age-related macular degeneration. The Sequenom Bioscience segment provides technology and research use only tools, such as the MassARRAY System platform, chip and reagent consumables, software, and biomarker assay panels for genetic analysis and applications in translational research, clinical research, pharmacogenomics, oncology, and agricultural genomics. Its MassARRAY systems are used in a range of DNA/RNA analysis applications, including SNP, genotyping, detection of mutations, analysis of copy number variants, and other structural genome variations, as well as in quantitative gene expression analysis, quantitative DNA methylation analysis, comparative sequence analysis of haploid organisms, SNP discovery, and oligonucleotide quality control. This segment also provides contract research services to clinical research laboratories, bioagriculture, biotechnology and pharmaceutical companies, academic institutions, and government agencies. The company was founded in 1994 and is headquartered in San Diego, California.

570 Employees
Last Reported Date: 02/27/14
Founded in 1994

sequenom inc (SQNM) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $400.0K
Chief Scientific and Strategy Officer
Total Annual Compensation: $375.0K
Consultant
Total Annual Compensation: $354.3K
Compensation as of Fiscal Year 2013.

sequenom inc (SQNM) Key Developments

Sequenom Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 09:20 AM

Sequenom Inc. Presents at 2014 Morgan Stanley Global Healthcare Conference, Sep-08-2014 09:20 AM. Venue: The Grand Hyatt Hotel, New York, New York, United States. Speakers: Carolyn D. Beaver, Chief Financial Officer, Chief Accounting Officer and Vice President, William J. Welch, Chief Executive Officer, President and Director.

Sequenom Enters into License Agreement with Mayo Medical Laboratories

Sequenom Inc. and Mayo Medical Laboratories have announced a license agreement for noninvasive prenatal testing patents and applications.

Sequenom Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

Sequenom Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter, the company reported total revenues of $39.8 million for the second quarter of 2014, an increase of 62% compared to revenues of $24.5 million for the second quarter of 2013. Loss from operations was $13.2 million, as compared to $29.2 million, for the same period in 2013. Net earnings was $4.5 million, or $0.04 per basic and diluted share, as a result of the sale of the Bioscience business in the second quarter of 2014, compared to a net loss of $31.0 million in the second quarter of 2013, or $0.27 per basic and diluted share. Loss from continuing operations was $8.36 million against $31.51 million a year ago. Net cash used in operating activities was $2.09 million against $34.36 million a year ago. Purchases of property, equipment and leasehold improvements were $0.146 million against $5.19 million a year ago. For the first half of 2014, the company reported revenues of $76.8 million, an increase of 43% from revenues of $53.6 million for the first half of 2013. Revenues improved primarily due to increased collections and higher test volumes. Loss from operations was $27.6 million, as compared to $56.0 million, for the same period in 2013. Net loss was $11.2 million, or $0.10 per basic and diluted share, as compared to net loss of $60.4 million, or $0.52 basic and diluted per share for the same period in 2013, reflecting the growth in revenue from the MaterniT21 PLUS test and the sale of the Bioscience business segment in 2014, including the related tax benefit for the loss on continuing operations for the first half of 2014. Net cash used in operating activities was $18.2 million for the first half of 2014, compared to $55.2 million in the same period in the prior year. The decrease in cash used in operating activities for the first half of 2014 is the result of the increase in revenue and the reduction in operating expenses. The change was not impacted by the operations or proceeds from the sale of the Bioscience business. Loss from continuing operations was $25.033 million against $60.50 million a year ago. Purchases of property, equipment and leasehold improvements were $0.551 million against $9.04 million a year ago.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SQNM:US $3.14 USD -0.11

SQNM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
AtriCure Inc $14.98 USD -0.38
Luminex Corp $19.21 USD -0.72
Pacific Biosciences of California Inc $5.01 USD -0.14
STAAR Surgical Co $11.33 USD -0.32
SurModics Inc $18.72 USD +0.01
View Industry Companies
 

Industry Analysis

SQNM

Industry Average

Valuation SQNM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.0x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales 0.8x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SEQUENOM INC, please visit www.sequenom.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.